AI-Driving Nanobody Drug Development

 AI is revolutionizing nanobody/VHH discovery, replacing slow trial-and-error with generative models and protein language processing. By predicting 3D structures and molecular interactions in seconds, tools like AlphaFold, Rosetta, and specialized generative frameworks create tailored nanobody sequences designed to hit complex biological targets :

• De Novo Design: Rather than relying on animal immunization, generative AI  models construct novel nanobody sequences from scratch. 
• In Silico Optimization: Models systematically simulate and improve  binding affinity, stability, and human compatibility, radically reducing      lab screening time. 
• Agent-Based Workflows: Some platforms utilize collaborative AI teams (managing      diverse tasks like computational biology and immunology) to design      multi-epitope binders with exceptional binding profiles. 
• Developability Profiling: Specialized computational tools evaluate candidate      sequences early on for risks like aggregation or poor expression before      physical production begins.

 Cancer remains a leading cause of mortality worldwide, driving an urgent medical need for highly targeted, potent, and less toxic therapeutic modalities . Target  tumor-associated antigens (TAAs) preferentially expressed on malignant cells compared to normal healthy tissues has revolutionized precision oncology. TAAs serve as critical molecular targets for delivering cytotoxic or cytostatic agents via antibody-drug conjugates (ADCs) or directing cellular immunity via chimeric antigen receptor (CAR) T or NK cells. 

Are your customers raving about you on social media? Share their great stories to help turn potential customers into loyal ones.

Several TAAs have established robust clinical validation as therapeutic nodes:

• Hematologic Malignancy Targets: CD19 and CD22 (B-cell malignancies, acute lymphoblastic leukemia (ALL), lymphomas); CD30 (Hodgkin   lymphoma, anaplastic large cell lymphoma); CD33 (acute myeloid  leukemia (AML)); CD38 and BCMA (multiple myeloma); and CD79b  (diffuse large B-cell lymphoma (DLBCL)).
• Solid Tumor Targets: HER2 (ERBB2) (breast, gastric, and gastroesophageal cancers); Nectin-4 (urothelial carcinoma); TROP-2 (triple-negative breast cancer, non-small cell lung cancer); Tissue      Factor (TF) (cervical and epithelial tumors); Folate Receptor-α  (FRα) (ovarian cancer); cMET (HGFR) and EGFR (NSCLC, gastric cancer, glioblastoma); GD2 (neuroblastoma, melanoma); CCR4     (T-cell lymphomas); CLDN18.2 (gastric and pancreatic adenocarcinomas); and GPC3 (hepatocellular carcinoma).

1. Anti-CD19

 Anti-CD19 nanobodies (VHH domains) that specifically bind to human CD19 with high affinity, as well as related multispecific constructs, chimeric antigen receptors (CARs), nanobody‑drug conjugates (NDCs), pharmaceutical compositions, polynucleotides, vectors, host cells and methods of use. The nanobodies bind to CD19 with a dissociation constant (KD) of about 0.05 nM to about 30 nM as measured by surface plasmon resonance, exhibit EC50 values in the range of about 0.2 nM to about 25 nM in ELISA, bind to CD19‑expressing cancer cells with EC50 values of about 0.3 nM to about 50 nM in flow cytometry, and have melting temperatures (Tm) of at least 60 °C. The nanobodies are useful for treating CD19‑expressing B‑cell malignancies such as B‑cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL) and non‑Hodgkin lymphoma (NHL), either as naked therapeutic agents, as components of CAR‑T cells, in multispecific formats, or as drug conjugates. 

2. Anti-CD38

Anti-CD38  nanobodies (VHH domains) that specifically bind to human CD38 with high affinity, as well as related multispecific constructs, chimeric antigen receptors (CARs), nanobody‑drug conjugates (NDCs), pharmaceutical compositions, polynucleotides, vectors, host cells and methods of use. The nanobodies bind to CD38 with a dissociation constant (KD) of about 0.05 nM to about 30 nM as measured by surface plasmon resonance, exhibit EC50 values in the range of about 0.2 nM to about 25 nM in ELISA, bind to CD38‑expressing cancer cells with EC50 values of about 0.3 nM to about 50 nM in flow cytometry, and have melting temperatures (Tm) of at least 60 °C. The nanobodies are useful for treating CD38‑expressing cancers such as multiple myeloma, chronic lymphocytic leukemia (CLL) and non‑Hodgkin lymphoma (NHL), either as naked therapeutic agents, as components of CAR‑T cells, in multispecific formats, or as drug conjugates.

3.  Anti-BCMA  

 Anti-BCMA nanobodies (VHH domains) that specifically bind to human B‑cell maturation antigen (BCMA) with high affinity, as well as related multispecific constructs, chimeric antigen receptors (CARs), nanobody‑drug conjugates (NDCs), pharmaceutical compositions, polynucleotides, vectors, host cells and methods of use. The nanobodies bind to BCMA with a dissociation constant (KD) of about 0.05 nM to about 30 nM as measured by surface plasmon resonance, exhibit EC50 values in the range of about 0.2 nM to about 25 nM in ELISA, bind to BCMA‑expressing cancer cells with EC50 values of about 0.3 nM to about 50 nM in flow cytometry, and have melting temperatures (Tm) of at least 60 °C. The nanobodies are useful for treating BCMA‑expressing cancers such as multiple myeloma, either as naked therapeutic agents, as components of CAR‑T cells, in multispecific formats, or as drug conjugates.

4. Anti-HER2

Anti-HER2  nanobodies (VHH domains) that specifically bind to human HER2 (ErbB2) with high affinity, as well as related multispecific constructs, chimeric antigen receptors (CARs), nanobody‑drug conjugates (NDCs), pharmaceutical compositions, polynucleotides, vectors, host cells and methods of use. The nanobodies bind to HER2 with a dissociation constant (KD) of about 0.05 nM to about 30 nM as measured by surface plasmon resonance, exhibit EC50 values in the range of about 0.2 nM to about 25 nM in ELISA, bind to HER2‑expressing cancer cells with EC50 values of about 0.3 nM to about 50 nM in flow cytometry, and have melting temperatures (Tm) of at least 60 °C. The nanobodies are useful for treating HER2‑expressing cancers such as breast cancer, gastric cancer and ovarian cancer, either as naked therapeutic agents, as components of CAR‑T cells, in multispecific formats, or as drug conjugates .

5. Ant-Trop2

Anti-Trop2 nanobodies, their encoding polynucleotides, and methods of their use. The nanobodies specifically bind human and Cyno Trop2 with high affinity (KD of about 1-30 nM) and are useful for diagnosing and treating Trop2-expressing cancers, either as naked therapeutic agents or as components of multispecific constructs, drug conjugates, or radioimmunoconjugates.

6. Anti-Claudin 18.2 (CLDN18.2)

 Anti-Claudin 18.2 (CLDN18.2) nanobodies (VHH domains) that specifically bind to human Claudin 18.2 (CLDN18.2) with high affinity, as well as related multispecific constructs, chimeric antigen receptors (CARs), nanobody‑drug conjugates (NDCs), pharmaceutical compositions, polynucleotides, vectors, host cells and methods of use. The nanobodies bind to CLDN18.2 with a dissociation constant (KD) of about 0.05 nM to about 30 nM as measured by surface plasmon resonance, exhibit EC50 values in the range of about 0.2 nM to about 25 nM in ELISA, bind to CLDN18.2‑expressing cancer cells with EC50 values of about 0.3 nM to about 50 nM in flow cytometry, and have melting temperatures (Tm) of at least 60 °C. The nanobodies are useful for treating CLDN18.2‑expressing cancers such as gastric cancer, pancreatic cancer and gastroesophageal junction adenocarcinoma, either as naked therapeutic agents, as components of CAR‑T cells, in multispecific formats, or as drug conjugates.

7. Anti-EGFR

Ant-EGFR nanobodies (VHH domains) that specifically bind to human epidermal growth factor receptor (EGFR) with high affinity, as well as related multispecific constructs, chimeric antigen receptors (CARs), nanobody‑drug conjugates (NDCs), pharmaceutical compositions, polynucleotides, vectors, host cells and methods of use. The nanobodies bind to EGFR with a dissociation constant (KD) of about 0.05 nM to about 30 nM as measured by surface plasmon resonance, exhibit EC50 values in the range of about 0.2 nM to about 25 nM in ELISA, bind to EGFR‑expressing cancer cells with EC50 values of about 0.3 nM to about 50 nM in flow cytometry, and have melting temperatures (Tm) of at least 60 °C. The nanobodies are useful for treating EGFR‑expressing cancers such as non‑small cell lung cancer, colorectal cancer and glioblastoma, either as naked therapeutic agents, as components of CAR‑T cells, in multispecific formats, or as drug conjugates. 

8. Anti-GPC3

Ant-GPC3 nanobody  lead seq1 and seq3 are recommended as primary candidates for anti-GPC3 VHH development due to their favorable predicted binding profile and biophysical properties. Lead seq4 and seq10 may be explored for high-affinity applications with additional optimization .

9. Anti-CCR4

Anti- CCR4 nanobodies (VHH domains) that specifically bind to human C-C chemokine receptor type 4 (CCR4) with high affinity, as well as related multispecific constructs, chimeric antigen receptors (CARs), nanobody‑drug conjugates (NDCs), pharmaceutical compositions, polynucleotides, vectors, host cells and methods of use. The nanobodies bind to CCR4 with a dissociation constant (KD) of about 0.05 nM to about 30 nM as measured by surface plasmon resonance, exhibit EC50 values in the range of about 0.2 nM to about 25 nM in ELISA, bind to CCR4‑expressing cancer cells with EC50 values of about 0.3 nM to about 50 nM in flow cytometry, and have melting temperatures (Tm) of at least 60 °C. The nanobodies are useful for treating CCR4‑expressing cancers such as adult T‑cell leukemia/lymphoma (ATLL), cutaneous T‑cell lymphoma (CTCL) and peripheral T‑cell lymphoma (PTCL), either as naked therapeutic agents, as components of CAR‑T cells, in multispecific formats, or as drug conjugates.

10. Anti-GD2

Anti-GD2  nanobodies (VHH domains) that specifically bind to the disialoganglioside GD2 with high affinity, as well as related multispecific constructs, chimeric antigen receptors (CARs), nanobody‑drug conjugates (NDCs), pharmaceutical compositions, polynucleotides, vectors, host cells and methods of use. The nanobodies bind to GD2 with a dissociation constant (KD) of about 0.05 nM to about 30 nM as measured by surface plasmon resonance, exhibit EC50 values in the range of about 0.2 nM to about 25 nM in ELISA, bind to GD2‑expressing cancer cells with EC50 values of about 0.3 nM to about 50 nM in flow cytometry, and have melting temperatures (Tm) of at least 60 °C. The nanobodies are useful for treating GD2‑expressing cancers such as neuroblastoma, melanoma and osteosarcoma, either as naked therapeutic agents, as components of CAR‑T cells, in multispecific formats, or as drug conjugates.

11. Anti-cMET

Anti-cMET nanobodies (VHH domains) that specifically bind to human c-MET with high affinity, as well as related multispecific constructs, chimeric antigen receptors (CARs), nanobody‑drug conjugates (NDCs), pharmaceutical compositions, polynucleotides, vectors, host cells and methods of use. The nanobodies bind to c-MET with a dissociation constant (KD) of about 0.05 nM to about 30 nM as measured by surface plasmon resonance, exhibit EC50 values in the range of about 0.2 nM to about 25 nM in ELISA, bind to c-MET‑expressing cancer cells with EC50 values of about 0.3 nM to about 50 nM in flow cytometry, and have melting temperatures (Tm) of at least 60 °C. The nanobodies are useful for treating c-MET‑expressing cancers such as non‑small cell lung cancer, gastric cancer and glioblastoma, either as naked therapeutic agents, as components of CAR‑T cells, in multispecific formats, or as drug conjugates .